BioPharm International
April 01, 2009
Columns and Departments
22
4
Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.
April 01, 2009
Features
22
4
Follow a risk-based approach to maintain a state of control.
April 01, 2009
Features
22
4
Biodefense start-up companies have an abundance of options when seeking funding.
April 01, 2009
Columns and Departments
22
4
The FDA is poised to gain more authority and resources to ensure product quality.
April 01, 2009
Columns and Departments
22
4
"A systematic approach taken by a company involved making an assessment of internal capabilities, strengths, and needs before the selection process."
April 01, 2009
Columns and Departments
22
4
With all of the new expressions systems being developed, companies must decide what improved production and yield are really worth.
April 01, 2009
Cover
22
4
Can increase in ionic strength result in higher viscosity?
April 01, 2009
Columns and Departments
22
4
The 45 comments submitted raised concerns about legacy products and ongoing process monitoring.
April 01, 2009
Columns and Departments
22
4
The biopharmaceutical industry must continuously evolve to keep up with changing trends.
April 01, 2009
Columns and Departments
22
4
Cost modeling provides valuable insights to support strategic decision-making when implementing disposable technologies.